Medical 21, Inc. — SEC Form D Filing
Medical 21, Inc. filed an SEC Form D on October 22, 2026, reporting $550K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 22, 2026
- Amount reported
- $550K
- Round stage
- Seed stage based on the small $550,000 equity financing round intended for preliminary development and regulatory filing preparations.
- Industry
- Biotechnology
- Website
- https://medical21.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: MINNESOTA
Problem
Coronary artery bypass surgeries currently require harvesting a patient's own blood vessels, creating additional surgical incisions, pain, complications, and extended recovery times.
Solution
Medical 21 builds the Maverics regenerative artificial artery, a synthetic graft featuring a resorbable polymer scaffold and nitinol reinforcement that eliminates the need to harvest host vessels.
Why now
Recent advancements in bioresorbable polymers and micro-structural nitinol fabrication now allow artificial grafts to support tissue regeneration and safely reabsorb into the body.
Source: SEC EDGAR Form D filing